Raison, C.L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B.W., Brown, R.T., Kakar, R., Hassman, M., Trivedi, R.P., Robison, R., Gukasyan, N., Nayak, S.M., Hu, X., O'Donnell, K.C., Kelmendi, B., Sloshower, J., Penn, A.D., Bradley, E., Kelly, D.F., Mletzko, T., Nicholas, C.R., Hutson, P.R., Tarpley, G., Utzinger, M., Lenoch, K., Warchol, K., Gapasin, T., Davis, M.C., Nelson-Douthit, C., Wilson, S., Brown, C., Linton, W., Johnson, M.W., Ross, S., Griffiths, R.R. (2023) JAMA , 330(9) , 843
Zusammenfassung
Phase 2 randomized clinical trial at 11 US research sites with 104 participants. Psilocybin 25 mg with psychological support was associated with significantly reduced depression scores compared to niacin control from baseline to day 43 and day 8.